-
Phase 1/Phase 2
-
-
18+Age Range
-
Active, Not Recruiting
Active, Not Recruiting
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.
Inclusion Criteria: - Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. - Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Participants must have a life expectancy of at least 3 months at the time of first dose. Exclusion Criteria: - Untreated symptomatic central nervous system metastases or leptomeningeal metastases. - Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts. - Participants with an active, known, or suspected autoimmune disease. Other protocol-defined inclusion/exclusion criteria apply.
Experimental: Part A: BMS-986442 + Nivolumab
Experimental: Part B1: BMS-986442 + Nivolumab
Experimental: Part B2: BMS-986442 + Nivolumab
Experimental: Part C: BMS-986442 + Nivolumab + Docetaxel
Experimental: Part D: BMS-986442 + Nivolumab + Carboplatin + Pemetrexed
Experimental: Part E: BMS-986442 + Nivolumab + Carboplatin + Paclitaxel